TOP
Nav Bar
  1. General Info
  2. Effects Info
  3. Reference
Drug Interaction Details
01. General Information
Pair Name Tubeimoside I, Temozolomide
Phytochemical Name Tubeimoside I (PubChem CID: 6110917 )
Anticancer drug Name Temozolomide (PubChem CID: 5394 )
Structure of
Phytochemical
2D-img
Download
2D MOL 3D MOL
Structure of
Anticancer Drug
2D-img
Download
2D MOL 3D MOL
02. Combinatorial Therapeutic Effect(s)
Synergistic Effect
Hide/Show
Enhancing Drug Efficacy
Hide/Show
Combination Pair ID: 249
Pair Name Tubeimoside I, Temozolomide
Disease Info [ICD-11: 2A00] Glioblastoma multiforme Investigative
Biological Phenomena Induction-->Apoptosis
Gene Regulation Down-regulation Phosphorylation AKT1 hsa207
Down-regulation Expression EGFR hsa1956
Down-regulation Expression MGMT hsa4255
Down-regulation Phosphorylation MTOR hsa2475
Down-regulation Phosphorylation NFKB1 hsa4790
Up-regulation Cleavage PARP1 hsa142
Down-regulation Phosphorylation PIK3CA hsa5290
Down-regulation Phosphorylation RELA hsa5970
Down-regulation Phosphorylation RHOBTB2 hsa23221
In Vitro Model U-118MG Astrocytoma Homo sapiens (Human) CVCL_0633
T98G Glioblastoma Homo sapiens (Human) CVCL_0556
Result We first demonstrated that synergistic effects of TBMS1 and TMZ induced apoptosis in GBM cells through reducing MGMT expression and inhibiting the EGFR induced PI3K/Akt/mTOR/NF-κB signaling pathway. This study provides a rationale for combined application of TMZ and TBMS1 as a potential chemotherapeutic treatment for MGMT+ GBM patients.
03. Reference
No. Title Href
1 Tubeimoside-I sensitizes temozolomide-resistant glioblastoma cells to chemotherapy by reducing MGMT expression and suppressing EGFR induced PI3K/Akt/mTOR/NF-κB-mediated signaling pathway. Phytomedicine. 2022 May;99:154016. doi: 10.1016/j.phymed.2022.154016. Click
It has been 47214 visits since 2024.08
If you find any error in data or bug in web service, please kindly report it to Dr. Zhang
TOP